PRNewswire (Tue, 14-Jul 8:00 AM ET)
PRNewswire (Wed, 8-Jul 8:00 AM ET)
PRNewswire (Tue, 16-Jun 8:00 AM ET)
Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
PRNewswire (Tue, 12-May 7:01 AM ET)
PRNewswire (Mon, 4-May 8:00 AM ET)
PRNewswire (Mon, 20-Apr 8:00 AM ET)
Market Chameleon (Mon, 16-Mar 6:29 AM ET)
Acurx Unveils Promising Microbiome-Sparing Antibiotics: Class Effect May Revolutionize CDI Treatment
Market Chameleon (Tue, 28-Oct 5:09 AM ET)
Market Chameleon (Thu, 9-Oct 4:19 AM ET)
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
Acurx Pharmaceuticals trades on the NASDAQ stock market under the symbol ACXP.
As of July 16, 2026, ACXP stock price declined to $1.59 with 89,602 million shares trading.
ACXP has a beta of -2.65, meaning it tends to be less sensitive to market movements. ACXP has a correlation of 0.04 to the broad based SPY ETF.
ACXP has a market cap of $6.83 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ACXP traded as high as $176.40 and as low as $1.33.
The top ETF exchange traded funds that ACXP belongs to (by Net Assets): VXF.
ACXP has underperformed the market in the last year with a return of -81.7%, while the SPY ETF gained +21.9%. In the last 3 month period, ACXP fell short of the market, returning -48.7%, while SPY returned +7.5%. However, in the most recent 2 weeks ACXP has outperformed the stock market by returning +3.9%, while SPY returned +0.7%.
ACXP support price is $1.65 and resistance is $1.85 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACXP shares will trade within this expected range on the day.